New Guidance Puts PBM Transparency Lawsuit in Limbo

Mere days after the top PBM trade group filed suit against a regulation requiring PBMs to report historical net prices of prescription drugs, the Biden administration issued guidance that effectively says that provision won’t be enforced anytime soon.

Still, it’s not yet certain what the Pharmaceutical Care Management Association (PCMA) or the U.S. Chamber of Commerce — which filed a similar suit against the so-called “transparency in coverage” rule — plan to do regarding their litigation. And one health plan trade group wants the administration to do more to address its concerns about the price transparency regulation.

© 2022 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

pills
September 22

Report Shows Limited Access to Opioid Use Disorder Treatments for Medicare Beneficiaries

READ MORE
cms-website
September 22

Drug Price Negotiation Will Require New CMS Regulations, Staffing

READ MORE
money-stethoscope
September 22

Study: Pharma Companies Often Profit From Donations to Patient Assistance Charities

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today